期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 12, 期 -, 页码 2431-2442出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S170840
关键词
astragaloside IV; podocyte dedifferentiation; mesangial cell activation; miR-21; beta-catenin pathway; TGF-beta 1/Smads pathway; renal fibrosis
资金
- Major National Basic Research Program of China (973 Program) [2012CB518602]
- Scientific Research Project of Beijing Educational Committee [KZ201610025024]
Background: Podocytc dedifferentiation andmesangial cell (MC) activation play an important role in many glomerular diseases associated with fibrosis. MieroRNA-21 (miR-21) is closely linked to renal fibrosis, but it is unknown whether and how miR-21 promotes podocyte dedifferentiation and MC activation and whether astragaloside IV (AS-IV) improves renal function and fibrosis through the regulation of miR-21. Materials and methods: Cultured MCs, primary mouse podocytes, and diabetic KK-Ay mice were treated with AS-IV. Cell transfection, Western blot, real-time PGR, immunofluorescence assay, immunohistocliemica 1 assay, and electronic microscopy were used to detect the markers of podocyte dedifferentiation and MC activation and to observe the renal morphology. Results: Our data showed that miR-21 expression was increased and that AS-IV decreased miR-21 levels in cells, serum, and kidney. ()verexpressed miR-21 promoted podocyte dedifferentiation and MC activation, and treatment with AS-IV reversed this effect. Furthermore, the overexpression of miR-21 activated the beta-catenin pathway and the transforming growth factor (TGF)-beta 1/Smads pathway in the process of podocyte dedifferentiation andMC activation, which was abolished by AS-IV treatment. In addition, both tlie Wnt/beta-catenin pathway inhibitor XAV-939 and tlie TGF-beta 1/Smads pathway inhibitor SB431542 reversed the effect of AS-IV. Furthermore, AS-IV improved renal function and fibrosis in diabetic KK-Ay mice. Conclusion: Our results indicated that AS-IV ameliorates renal function and renal fibrosis by inhibiting miR-21 overexpression-induced podocyte dedifferentiation and MC activation in diabetic kidney disease. These findings pave way for future studies investigating AS-IV as a potential therapeutic agent in the management of glomerular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据